Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Patent
1997-05-13
1999-07-20
Weddington, Kevin E.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
5142262, 514315, 514318, 514646, A61K 3155, A61K 3154, A61K 31445, A61K 31135
Patent
active
059256346
ABSTRACT:
This invention discloses that ibogaine, a plant derivative, can be used safely to treat neuropathic pain (i.e, pain which does not respond conventionally to opiate drugs such as morphine). Ibogaine functions inside the CNS as an NMDA antagonist which is inherently safe, even at relatively high dosages (including dosages high enough to cause hallucinations). Ibogaine does not cause the neurotoxic side effects caused by other NMDA antagonist drugs; this relative safety of ibogaine is due to antagonist activity at neuronal sigma receptors, which had not been known prior to discovery by the Applicant. Ibogaine can also be used for this purpose in combination with additional drugs such as (1) drugs which activate alpha-2 adrenergic receptors; (2) drugs which block the kainic acid subclass of glutamate receptors; or, (3) anti-cholinergic agents that suppress activity at muscarinic acetylcholine receptors. Such drug combinations can reduce or avoid the hallucinatory effects of ibogaine, if desired.
REFERENCES:
patent: 4499096 (1985-02-01), Lotsof
patent: 4587243 (1986-05-01), Lotsof
patent: 4857523 (1989-08-01), Lotsof
patent: 5026697 (1991-06-01), Lotsof
patent: 5034400 (1991-07-01), Olney
patent: 5152994 (1992-10-01), Lotsof
patent: 5605911 (1997-02-01), Olney et al.
patent: 5629307 (1997-05-01), Olney
Deecher, D.C. et al, "Mechanisms of action of ibogaine and harmaline congeners based on radioligand studies," Brain Res. 571: 242-247 (1992).
Glick, S.D., et al, "Effects and aftereffects of ibogaine on morphine self-administration in rats," Eur. J. Pharmacol. 195: 341-435 (1991).
Glick, S.D., et al, "Local effects of ibogaine on extracellular levels of dopamine and its metabolites in nucleus accumbens and striatum," Brain Res. 628: 201-208 (1993).
Green, P.G., et al, "Antinociception opioids and the cholinergic system," Progress in Neurobiology 26: 119-146 (1986).
Harsing, L.G., et al, "Evidence that ibogaine releases dopamine from the cytoplasmic pool in isolated mouse striatum," J. Neural. Transm. Gen. Sect. 96: 215-25 (1994).
Popik, P., et al, "The putative anti-addictive drug ibogaine is a complex, " Psychopharmacology 114: 672-674 (1994).
Sershen, H., et al, "Ibogaine antagonizes cocaine-induced locomotor stimulation in mice," Life Sci 50: 1079-1086 (1992).
Sershen, H., et al, "Ibogaine reduces preference for cocaine consumption in C57BL/6By mice," Pharmacol Biochem Behav 47: 13-19 (1994).
Sershen, H., "Effect of ibogaine on serotonergic and dopaminergic interactions in striatum from mice and rats," Neurochem. Res. 19: 1463-1464 (1994).
Sershen, H., et al, "The effect of ibogaine on kappa-opioid-and 5-HT3-induced changes in stimulation-evoked dopamine release in vitro from striatum of C57BL/6By mice," Brian Res. Bull. 36: 587-591 (1995).
Kelly Patrick D.
Washington University
Weddington Kevin E.
LandOfFree
Use of ibogaine for treating neuropathic pain does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of ibogaine for treating neuropathic pain, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of ibogaine for treating neuropathic pain will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1322009